Karnataka seeks wider price caps beyond cancer medicines on other high-cost life-saving drugs

The regulation of drug prices in India is a critical aspect of public health governance, primarily managed through the Drugs (Prices Control) Order, 2013 (DPCO). The DPCO, issued under the Essential Commodities Act, 1955, empowers the National Pharmaceutical Pricing Authority (NPPA) to fix the ceiling prices of essential medicines. Currently, medicines listed in the National List of Essential Medicines (NLEM) (Schedule I of the DPCO) are subject to price caps, meaning their Maximum Retail Price (MRP) is strictly regulated. However, for 'non-scheduled' drugs—those outside this list—manufacturers have historically been allowed to increase prices by up to 10% annually. The recent move to invoke Paragraph 19 of the DPCO, which allows the government to cap prices of non-scheduled drugs in the 'public interest', demonstrates a shift towards regulating trade margins (the difference between the manufacturer's selling price and the MRP). The State's demand to include advanced chemotherapy and targeted therapies under the DPCO highlights the governance challenge of balancing pharmaceutical innovation (which requires high returns) with public health needs (which require affordable access).

Access to affordable healthcare is implicitly recognized under Article 21 of the Indian Constitution, which guarantees the right to life. The high Out-of-Pocket Expenditure (OOPE) on healthcare in India—often driven by exorbitant drug costs—frequently pushes vulnerable populations below the poverty line. The Karnataka government's push for broader price caps on high-cost treatments for non-communicable diseases (NCDs) like cardiac and kidney ailments addresses a critical equity issue. By calling for transparency in hospital billing—requiring the disclosure of both the purchase cost and the MRP—the State aims to tackle the issue of profiteering within the healthcare supply chain. This aligns with the broader goal of Universal Health Coverage (UHC), where individuals can access necessary healthcare without suffering financial hardship. From a UPSC perspective, understanding the impact of high medicine costs on the catastrophic health expenditure of households is crucial when analyzing the effectiveness of schemes like Ayushman Bharat Pradhan Mantri Jan Arogya Yojana.

The pharmaceutical market in India often suffers from market failure, primarily due to information asymmetry; the doctor prescribes the drug, and the patient, lacking knowledge, simply buys it. This dynamic allows for significant mark-ups between the ex-factory price and the final MRP. The proposed 30% cap on trade margins for non-scheduled anti-cancer drugs aims to correct this inefficiency, potentially saving patients an estimated ₹2,500 crore. However, excessive price controls can have unintended economic consequences. If profit margins are squeezed too tightly, it could deter Foreign Direct Investment (FDI) in the sector and disincentivize domestic companies from investing in Research and Development (R&D) for complex therapies. The challenge for policymakers is to design a regulatory framework that prevents price gouging while maintaining the viability and global competitiveness of the Indian pharmaceutical industry, often dubbed the 'pharmacy of the world'. Therefore, the expert committee's role in identifying the specific drugs for price control is critical to ensure a balanced approach that promotes allocative efficiency in the health sector.